Stockreport

Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat [Yahoo! Finance]

Opko Health, Inc.  (OPK) 
Last opko health, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.opko.com
PDF On October 29, 2025, Guggenheim lifted GeneDx (NASDAQ:WGS) to a $170 price target (Buy) after the company's blow-out Q3 announcement a day earlier. GeneDx had just repo [Read more]